ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Budget impact analysis of Oncotype DX
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the mid-term budget impact of using the Oncotype DX
methodsA budget impact analysis was conducted from the perspective of the Italian National Health Service (SSN) over a 5-year time horizon. The analysis compared a strategy using MPT to inform chemotherapy (CT) decisions versus standard clinical practice. A hybrid decision-tree and cohort state-transition model was employed, utilizing data primarily from the Italian BONDx study. Sensitivity analyses, including probabilistic and univariate analyses, were performed to assess the robustness of the results and to determine the test price required to offset the budget impact over a five-year time horizon.
resultsIn the base-case scenario where all ER+/HER2- EBC patients receive the test, MPT use led to a 40.2% reduction in CT prescription. However, the overall budget impact was positive, with an additional cost of €106.1 million (95%CrI 98.5 to 113.6) over five years (approximately €21 million per year), mainly due to the acquisition costs of the MPTs. The maximum cost of the test to have a null budget impact in this scenario was estimated at €560. A scenario where MPTs were only applied to patients with a pre-test CT recommendation based on clinical-pathological criteria showed instead potential annual savings of €5.6 million (-€28.1 million in total, 95%CrI - 36.5 to -19.7).
conclusionImplementing MPTs in ER+/HER2- EBC management in Italy significantly affects CT prescription rates and healthcare expenditures. While MPTs reduce unnecessary CT and related adverse events, their high upfront cost necessitates strategic policy measures to ensure cost-effective implementation. Targeted MPT strategies, focusing on patients with a pre-test chemotherapy recommendation, demonstrate greater efficiency and potential savings for the Italian NHS.
Indexed as
Identifiers
42159890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.